Beta-blocker therapy in decompensated heart failure was associated with significantly higher parasympathetic cardiac activity, including a greater percentage of R-R intervals with >50 ms variation (7.7% vs 4.9%, P=0.006).
Observational (n=199)
Do beta-blockers improve heart rate variability and neurohormonal profiles in patients with decompensated congestive heart failure?
Beta-blockers are associated with improved cardiac autonomic regulation, specifically higher parasympathetic modulation, in patients with decompensated heart failure.
Absolute Event Rate: 7.7% vs 4.9%
p-value: p=0.006
BACKGROUND: One of the putative mechanisms for the salutary effects of beta-blockers in patients with congestive heart failure (CHF) is their ability to improve autonomic dysfunction. However, patients with profound neurohumoral abnormalities derive little survival benefit from beta-blockers. The purpose of the current study was to evaluate the effect of beta-blockers on heart rate variability (HRV) in decompensated CHF. METHODS: Time and frequency domain HRV indices were obtained from 24-hour Holter recordings and compared to assess the role of beta-blockade in 199 patients (mean age 60 +/- 14 years) with decompensated CHF. Neurohormonal differences were assessed by measuring norepinephrine, endothelin-1, tumor necrosis factor-alpha, and interleukin-6 in a subset of 64 patients. RESULTS: All HRV indices were markedly suppressed but were substantially higher in patients who were on beta-blockers. Time domain measures of parasympathetic cardiac activity, the percentage of R-R intervals with > 50 ms variation (4.9 +/- 0.6 vs 7.7 +/- 1.2%, P = 0.006) and the square root of mean squared differences of successive R-R intervals (22.7 +/- 2.0 vs 31.6 +/- 4.1 ms, P = 0.004), were higher in the beta-blocker group. Spectral analysis revealed that the total power and the ultra-low frequency power were significantly higher in patients on beta-blockers (82% and 59%, respectively). The high frequency power, a spectral index of parasympathetic modulation, was 41% higher in the beta-blocker group (121 +/- 25 vs 171 +/- 27 ms(2), P = 0.02). Norepinephrine and interleukin-6 levels were substantially lower in patients on beta-blockers (28% and 61%, respectively). However, these differences did not reach statistical significance. CONCLUSIONS: Beta-blockers improve the impaired cardiac autonomic regulation during high sympathetic stress of decompensated CHF. This effect may play an important role in protecting the myocardium and preventing arrhythmias during transient increases in sympathetic activity.
Aronson et al. (Sun,) conducted a observational in Decompensated heart failure (n=199). Beta-blockers vs. No beta-blockers was evaluated on Percentage of R-R intervals with > 50 ms variation (p=0.006). Beta-blocker therapy in decompensated heart failure was associated with significantly higher parasympathetic cardiac activity, including a greater percentage of R-R intervals with >50 ms variation (7.7% vs 4.9%, P=0.006).